As the use of TAVI expands into younger and lower-risk populations, long-term durability and clinical outcomes are at the forefront of decision-making.
In these two new Drivetime interviews, A/Prof. Justin Mariani speaks with leading interventional cardiologists to examine 5-year data from the Evolut Low Risk trial and its implications for contemporary Australian practice.
<< Login to stream the interviews below or access our private podcast. If you don’t have a login, subscribe for free now! >>
TAVI in Low-Risk Patients (VIC Perspective)
As the use of TAVI expands into younger and lower-risk populations, long-term durability and clinical outcomes are at the forefront of decision-making.
In this interview A/Prof. Justin Mariani speaks with a leading interventional cardiologist from Melbourne, to examine 5-year data from the Evolut Low Risk trial and its implications for contemporary Australian practice.
They discuss the evolving evidence, valve durability, and haemodynamics, and how the latest findings are reshaping referral pathways, shared decision-making and patient selection.
Associate Professor & Cardiologist, The Alfred Hospital, Melbourne.
Structural Interventionist, Deputy Director of the Alfred Hospital.
TAVI in Low-Risk Patients (NSW Perspective)
As the use of TAVI expands into younger and lower-risk populations, long-term durability and clinical outcomes are at the forefront of decision-making.
In this interview A/Prof. Justin Mariani speaks with a leading interventional cardiologist from Sydney, to examine 5-year data from the Evolut Low Risk trial and its implications for contemporary Australian practice.
They discuss the evolving evidence, valve durability, and haemodynamics, and how the latest findings are reshaping referral pathways, shared decision-making and patient selection.
Associate Professor & Cardiologist, The Alfred Hospital, Melbourne.
Cardiologist, St Vincent’s Hospital, Sydney.
Tap the share icon
and select 'Add to Home Screen' to add the site to your home screen for quick access!